Benzinga FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication
The FDA has approved Omeros Corporation's Yartemlea for TA-TMA, a fatal complication of stem-cell transplantation, with a 61% success rate. read more
The FDA has approved Omeros Corporation's Yartemlea for TA-TMA, a fatal complication of stem-cell transplantation, with a 61% success rate. read more